60239-18-1Relevant articles and documents
Cherenkov Radiation-Mediated In Situ Excitation of Discrete Luminescent Lanthanide Complexes
Cosby, Alexia G.,Ahn, Shin Hye,Boros, Eszter
, p. 15496 - 15499 (2018)
Lanthanide luminescence, while ideal for in vivo applications owing to sharp emission bands within the optical window, requires high-intensity, short-wavelength excitation of small organic “antenna” chromophores in the vicinity of the lanthanide complex to access excited f-orbital states through intersystem crossing. Herein, we explored Cherenkov radiation of the radioisotopes 18F and 89Zr as an in situ source of antenna excitation. The effective inter- and intramolecular excitation of the terbium(III) complexes of a macrocylic polyaminocarboxylate ligand (hydration number (q)=0, quantum yield (φ)=47 %) as well as its analogue functionalized to append an intramolecular Cherenkov excitation source (q=0.07, φ=63 %) was achieved. Using conventional small-animal fluorescence imaging equipment, we have determined a detection limit of 2.5 nmol of Tb(III) complex in presence of 10 μCi of 18F or 89Zr. Our system is the first demonstration of the optical imaging of discrete luminescent lanthanide complexes without external short-wave excitation.
Photoresponsive host-guest chemistry and relaxation time of fluorinated cyclodextrin and T1=T* 2 arylazopyrazole-functionalized DOTA metal complexes
Simke, Julian,B?ckermann, Till,Bergander, Klaus,Klabunde, Sina,Hansen, Michael Ryan,Ravoo, Bart Jan
supporting information, p. 2186 - 2191 (2021/03/24)
Light-responsive modulation of the longitudinal (T1) and transversal T *2) relaxation times of a fluorinated cyclodextrin has been achieved by host-guest complexation with arylazopyrazole-modified metal complexes in aqueous solution. This supramolecular concept can potentially be applied to the development of contrast agents for19F magnetic resonance imaging (MRI).
METHOD FOR PREPARING 1,4,7,10-TETRAAZACYCLODODECANE-1,4,7,10-TETRAACETIC ACID
-
Paragraph 0146; 0147, (2020/12/01)
Disclosed is a method for preparing 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) of formula (II), comprising the following steps: carrying out an alkylation reaction on cyclen in formula (I) and XCH2COOR in the presence of an acid-binding agent in water; adjusting a pH value to separate out a crude product of DOTA; and recrystallizing. The preparation method of the present invention is applicable to large-scale industrial production of DOTA, the whole process does not need to adopt an ion-exchange resin or low-temperature refrigeration mode for purification, and the purity and yield of the product are higher.
Method for preparing contrast agent
-
Paragraph 0005; 0058-0061, (2020/07/24)
The invention provides a method for preparing a contrast agent. Specifically, the preparation method comprises the following steps: enabling a complex liquid composition containing a macrocyclic chelate and lanthanide elements to sequentially pass through Relite CNS cationic resin and Relite 3As anionic resin to obtain a high-purity liquid solution, and then adjusting the pH value of the solution;and freeze-drying or low-temperature spray-drying to obtain a contrast agent solid, and further weighing a certain amount of the solid to prepare a contrast agent preparation for medical contrast.
General Approach to Direct Measurement of the Hydration State of Coordination Complexes in the Gas Phase: Variable Temperature Mass Spectrometry
Racow, Emily E.,Kreinbihl, John J.,Cosby, Alexia G.,Yang, Yi,Pandey, Apurva,Boros, Eszter,Johnson, Christopher J.
supporting information, p. 14650 - 14660 (2019/10/11)
The formation of ternary aqua complexes of metal-based diagnostics and therapeutics is closely correlated to their in vivo efficacy but approaches to quantify the presence of coordinated water ligands are limited. We introduce a general and high-throughput method for characterizing the hydration state of para- and diamagnetic coordination complexes in the gas phase based on variable-temperature ion trap tandem mass spectrometry. Ternary aqua complexes are directly observed in the mass spectrum and quantified as a function of ion trap temperature. We recover expected periodic trends for hydration across the lanthanides and distinguish complexes with several inner-sphere water ligands by inspection of temperature-dependent speciation curves. We derive gas-phase thermodynamic parameters for discernible inner- and second-sphere hydration events, and discuss their application to predict solution-phase behavior. The differences in temperature at which water binds in the inner and outer spheres arise primarily from entropic effects. The broad applicability of this method allows us to estimate the hydration states of Ga, Sc, and Zr complexes under active preclinical and clinical study with as-yet undetermined hydration number. Variable-temperature mass spectrometry emerges as a general tool to characterize and quantitate trends in inner-sphere hydration across the periodic table.
Including and Declaring Structural Fluctuations in the Study of Lanthanide(III) Coordination Chemistry in Solution
Nielsen, Lea Gundorff,S?rensen, Thomas Just
, (2019/11/14)
The physicochemical properties of lanthanide(III) ions are directly linked to the structure of the surrounding ligands. Rapid ligand exchange prohibits direct structure-property relationships from being formed for simple complexes in solution because the property measured will be an average over several structures. For kinetically inert lanthanide(III) complexes, the simpler speciation may alleviate the problem, yet the archetypical complexes formed by ligands derived from cyclen are known to have at least four different forms in solution - each with a variation in the crystal field that gives rise to significantly different properties. Slow interchange between forms has been engineered, so that a single complex geometry can be studied, but fast or intermediate interchange between forms is much more commonly observed. The rapid structural fluctuation can report on the changing chemical environment and can be disregarded if a specific property of a lanthanide(III) complex is exploited in an application. However, if we are to understand the chemistry of the lanthanide(III) ions in solution, we must include the structural fluctuation that takes place even in kinetically inert lanthanide(III) complexes in our studies. Here, we have scrutinized the processes that determine the speciation of lanthanide(III) complexes of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate (DOTA)-like ligands, in particular the processes that enable exchange between forms that have different physicochemical properties, exemplified by the exchange between the diastereomeric capped square-antiprismatic (cSAP) and capped twisted-square-antiprismatic (cTSAP) forms of DOTA-like lanthanide(III) complexes. In the characterization of a kinetically inert f-element complex, understanding the structural fluctuation in the system is critical because a single observed property can arise from a weighted average, from all forms present, or from a single form with a dominating contribution. Further, the experimental condition will influence both the distribution of lanthanide(III) species in solution and the rates of the processes that change the coordination sphere of the lanthanide(III) ions. This is highlighted using data from a series of cyclen-derived ligands with different pendant arms and different denticity. The data were obtained in experiments that take place on different time scales to show that the rate of the process that results in a structural change must be considered against the time of the experiment. We conclude that the structural fluctuations must be taken into account and that they cannot be predicted from the ligand structure. Thus, an estimate of the exchange rates between forms, the relative concentrations of the specific forms, and the effect of the specific structure of each form of the complex must be included in the description of the solution properties of f-element chelates.
Compositions for protecting skin
-
, (2018/05/29)
The purpose of the present invention is to provide a skin outer layer composition which does not have or has very low skin irritation or toxicity, and has a high ability to remove formaldehyde and heavy metals compared to conventional material. The present invention provides the skin outer layer composition comprising, as active ingredients, one or more selected from trientine or trientine derivatives represented by chemical formula 1, cyclen or cyclen derivatives represented by chemical formula 2, and cyclam or cyclam derivatives represented by chemical formula 3. In the above formulas, R_1, R_2, R_3, R_4, R_5 and R_6 are each independently hydrogen, -R_7-COOH or salts thereof, and R_7 is a C_1-C_5 aliphatic group, a substituted or unsubstituted aromatic group, or a heterocyclic six-membered or five-membered ring.COPYRIGHT KIPO 2018
Preparation method for 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid
-
Paragraph 0058-0061, (2018/11/03)
The invention relates to a preparation method for 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid. Specifically, the method uses a recrystallization method to obtain a high-purity compound represented by a formula I shown in the description, and further, meglumine and Gd2O3 are complexed with the compound represented by the formula I to obtain the gadoteric acid meglumine. The method disclosed by the invention is simple to operate, has low costs, and is green, environmentally friendly and suitable for large-scale production.
DOTA SYNTHESIS
-
Page/Page column 9; 10; 11, (2017/07/14)
The present invention provides methods for the preparation of compounds useful in vivo therapeutic and diagnostic applications. In particular, the present invention provides a method for the synthesis of 1,4,7,10-tetraazacyclododecane-1,4, 7,10- tetraacetic acid (DOTA) and also methods for the preparation of metal chelates of DOTA.
CA - 4 macrocyclic polyamine derivative and its anti-tumor properties
-
Paragraph 0096; 0098; 0099, (2017/10/07)
The invention discloses macrocyclic polyamine derivatives (represented by formula I) of CA-4 as well as a pharmaceutically acceptable salt or configurational isomers of the macrocyclic polyamine derivatives. The compounds can be used for inhibiting a tumor from genesis or growth. Substituent groups R1 and R2, ring A, and a linking group L are defined in the description. The invention further discloses a preparation method of the compounds shown as formula I, a medicament composition, and application of the compounds in treating tumor diseases.
